Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

155.08 +3.27 (+2.15%)
Streaming Delayed Price Updated: 10:30 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program. 
Via Stocktwits
Topics Economy Government
News headline image
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
News headline image
Here&#39;s How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
 
Via Benzinga
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study ↗
Via Stocktwits
News headline image
Gilead&#39;s Experimental Combo Tablet For HIV Treatment Hits Primary Goal ↗
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial. 
Via Benzinga
News headline image
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains ↗
Via MarketBeat
News headline image
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak ↗
Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead-partnered cancer regimen failed. 
Via Investor's Business Daily
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Gilead Sciences Inc. (NASDAQ:GILD) Presents a Compelling Profile for Value Investors ↗
Gilead Sciences (GILD) presents a strong value investing case, trading at a discount to its industry with high profitability, no debt, and improving earnings growth forecasts. 
Via Chartmill
News headline image
3 Profitable Stocks We Keep Off Our Radar
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
What Does the Market Think About Gilead Sciences Inc? ↗
 
Via Benzinga
News headline image
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Unpopular Stocks We Think Twice About
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗
Via MarketBeat
News headline image
Here&#39;s How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Top S&P500 movers in Friday's session ↗
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
News headline image
These S&P500 stocks are moving in today's session ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday. 
Via Chartmill
News headline image
Gapping S&P500 stocks in Friday's session ↗
Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Kymera (KYMR) Q3 2025 Earnings Call Transcript ↗
Kymera (KYMR) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Gilead Sciences Inc (NASDAQ:GILD) Demonstrates Strong Dividend Reliability and Profitability ↗
Gilead Sciences (GILD) is a reliable dividend stock with a 2.53% yield, 10-year payment history, and a low payout ratio. Strong profitability and a debt-free balance sheet support its sustainable... 
Via Chartmill
News headline image
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
From Gilead Sciences, Inc.
Via Business Wire
News headline image
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Gilead Sciences Inc Chart Analysis ↗
Technical analysis on the stock chart for GILD. 
Via Talk Markets
News headline image
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment ↗
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.